A New Standard of Care for Some Advanced Esophageal Cancer Patients

Pembrolizumab showed promise in the second-line setting for patients with metastatic esophageal cancer and high PD-L1 expression.

Source: CancerNetwork - January 18, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news